First-line pharmacotherapies for depression - What is the best choice?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 7-8, 2009, Pages 478-486

  Koenig, Aaron M ^a   Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antidepressants; Bupropion; Depression; Selective serotonin reuptake inhibitors (SSRIs); Serotonin and norepinephrine reuptake inhibitors (SNRIs)

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATION; BLOOD PRESSURE; BLURRED VISION; CHILL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FALLING; HUMAN; HYPERTENSION; INSOMNIA; LIVER FAILURE; MAJOR DEPRESSION; MUSCLE TWITCH; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERCEPTION DISORDER; PRIAPISM; PULMONARY HYPERTENSION; PULSE RATE; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; TREATMENT RESPONSE; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 69249097101     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.743     Document Type: Review

References (78)

1. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000; 157: 1-45.
2. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007; 8: 67-104. (Pubitemid 46690921)
3. Thase ME, Kupfer DJ. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol. 1996; 64: 646-659. (Pubitemid 26274526)
4. Depression in primary care. United States. Depression Guideline Panel. Rockville, Md. US Department of Health and Human Services, Agency for Health Care Policy and Research. Washington, D.C. For sale by the U.S. G.P.O.; 1993.
5. Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006; 11: 12-21.
6. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991; 48: 851-855.
7. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 52-62.
8. Beck AT, Steer RA, Brown GK. Manual for the BDI-II. San Antonio, TX: The Psychological Corporation; 1996.
9. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006; 31: 1841-1853.
10. Thase ME. Achieving remission and managing relapse in depression. J Clin Psychiatry. 2003; (64 Suppl) 18: 3-7.
11. Thase ME, Denko T. Pharmacotherapy of mood disorders. Annu Rev Clin Psychol. 2008; 4: 53-91.
12. Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA. 2002; 287: 203-209. (Pubitemid 34251945)
13. Mulrow CD, Williams JW Jr, Trivedi M, et al. 1999. Treatment of depression. Newer Pharmacotherapies. AHCPR Publ. 99-E014. Rockville, MD: Agency Health Care Policy Res. Available at http://www.ncbi.nlm.nih.gov/ books/bv.fcgi?rid=hstat1.chapter.9286.
14. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002; 325: 1332-1333.
15. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999; 57: 507-533. (Pubitemid 29196919)
16. Gutman DA, Owens MJ. Serotonin and norepinephrine transporter binding profile of SSRIs. Essent Psychopharmacol. 2006; 7: 35-41.
17. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major dep ressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci. 2006; 31: 122-131.
18. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373: 746-758.
19. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. 2007; 167: 1246-1251.
20. Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007; 167: 188-194. (Pubitemid 46148067)
21. Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry. 2002; 159: 1667-1673.
22. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006; 295: 499-507. (Pubitemid 43200344)
23. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005; 293: 2372-2383. (Pubitemid 40676760)
24. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006; 354: 579-587. (Pubitemid 43209105)
25. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 2684-2692. (Pubitemid 47001036)
26. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007; 29: 918-926. (Pubitemid 47223423)
27. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med. 2007; 356: 2675-2683. (Pubitemid 47001035)
28. Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991; 303: 685-692.
29. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992; 268: 3441-3445. (Pubitemid 23002748)
30. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-210. (Pubitemid 20060476)
31. Andrade C, Bhakta SG, Singh NM. Controversy revisited: Selective serotonin reuptake inhibitors in paediatric depression. World J Biol Psychiatry. 2006; 7: 251-260. (Pubitemid 44650535)
32. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007; 297: 1683-1696.
33. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. Br J Psychiatry. 2006; 189: 393-398. (Pubitemid 44683169)
34. Mann JJ, Emslie G, Baldessarini RJ, et al. ACNP Task Force report on SSRIs and suicidal behavior in youth. Neuropsychopharmacology 2006; 31: 473-492. (Pubitemid 43276964)
35. Pfeffer CR. The FDA pediatric advisories and changes in diagnosis and treatment of pediatric depression. Am J Psychiatry. 2007; 164: 843-846. (Pubitemid 46972894)
36. Simon GE. The antidepressant quandary: considering suicide risk when treating adolescent depression. N Engl J Med. 2006; 355: 2722-2723.
37. Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007; 164: 1035-1043. (Pubitemid 47121392)
38. Akiskal HS, Benazzi F, Perugi G, et al. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J Affect Disord. 2005; 85: 245-258.
39. Thase ME. Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol. 2006; 18: 1213-1230. (Pubitemid 46389735)
40. Kurian B, Arbogast P, Ray W, et al. Effect of government regulatory changes on SSRI prescriptions in children. Pharmacoepidemiol Drug Saf. 2006; 15 (Suppl): S33.
41. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidally data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64: 466-472. (Pubitemid 46556464)
42. Gibbons RD, Hur K, Bhaumik DK, et al. The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry. 2006; 163: 1898-1904. (Pubitemid 44807781)
43. McKeown RE, Cuffe SP, Schulz RM. US suicide rates by age group, 1970-2002: an examination of recent trends. Am J Public Health. 2006; 96: 1744-1751.
44. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178: 234-241. (Pubitemid 32183606)
45. Nemeroff CB, Entsuah R, Benattia I, et al. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008; 63: 424-434.
46. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007; 62: 1217-1227. (Pubitemid 350060895)
47. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002; 180: 396-404. (Pubitemid 34499333)
48. Cipriani A, Barbui C, Brambilla R et al. Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry. 2006; 67: 850-864. (Pubitemid 44049083)
49. Thase ME, Sloan DM. Venlafaxine. In: Schatzberg AF, Nemeroff CB, eds. Essentials of Clinical Psychopharmacology. American Psychiatric Association, 2006: 159-170.
50. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59: 502-508.
51. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001; 24: 183-197.
52. Baldomero EB, Ubago JG, Cercos CL, et al. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005; 22: 68-76.
53. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354: 1231-1242.
54. Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol. 2006; 26: 250-258. (Pubitemid 43804616)
55. Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006; 318: 657-665. (Pubitemid 44061240)
56. Thase ME, Komstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009; 14: 144-154.
57. Frampton JE, Plosker GL. Duloxetine: a review of its use in the treatment of major depressive disorder. CNS Drugs. 2007; 21: 581-609. (Pubitemid 46991960)
58. Gupta S, Nihalani N, Masand P. Duloxetine: review of its pharmacology, and therapeutic use in depression and other psychiatric disorders. Ann Clin Psychiatry. 2007; 19: 125-132. (Pubitemid 47035939)
59. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008; 42: 22-34. (Pubitemid 47570043)
60. Thase ME, Pritchett VL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007; 27: 672-676. (Pubitemid 351339455)
61. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Investig. 2007; 27: 481-492. (Pubitemid 46919700)
62. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007; 23: 401-416.
63. Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin. 2007; 23: 1605-1614. (Pubitemid 47122170)
64. Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7: 106-113. (Pubitemid 41783226)
65. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995; 56: 395-401.
66. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006; 6: 1249-1265.
67. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66: 974-981. (Pubitemid 41191788)
68. Clayton AH. Extended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity? Expert Opin Pharmacother. 2007; 8: 457-466.
69. Trivedi MH, Rush AJ, Carmody TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry. 2001; 62: 776-781.
70. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008; 42: 134-140.
71. Papakostas Gl, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006; 60: 1350-1355. (Pubitemid 44838537)
72. Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006; 26: 482-488.
73. Thase ME. Mirtazapine. In: Sadock B, Sadock V, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. Williams & Wilkins, 2006: 2851-2853.
74. Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001; 62: 358-361.
75. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001; 21: 425-431. (Pubitemid 32673032)
76. Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol. 2006; 26: 75-78. (Pubitemid 43167095)
77. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006; 163: 1161-1172. (Pubitemid 44464443)
78. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 1531-1541; quiz 1666. (Pubitemid 44465752)